 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- zabalafin hydrogel (AB-101a) / Alphyn Biologics
Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalfin (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2391;
Zabalafin demonstrated clinically meaningful results in pediatric and adult populations for itch and QOL improvement. Zabalafin is a promising unique topical AD drug for children and adults with the potential for limitless long-term continuous use.
- zabalafin hydrogel (AB-101a) / Alphyn Biologics
First in Human Phase 2 Trial of Zabalafin (AB-101): A Novel Topical Drug Candidate for Mild, Moderate and Severe Atopic Dermatitis in Children and Adults (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2294;
Zabalafin demonstrated clinically meaningful results in pediatric and adult populations for itch and QOL improvement. Zabalafin is a promising unique topical AD drug for children and adults with the potential for limitless long-term continuous use.
- | zabalafin hydrogel (AB-101a) / Alphyn Biologics
Trial completion: Study of topical AB-101 hydrogel versus vehicle in participants with atopic dermatitis. (EUDRACT) - Nov 2, 2023
P2, N=72, Completed, Sponsor: Alphyn Biologics Australia Pty. Ltd., a subsidiary of Alphyn Biologics, LLC
Zabalafin is a promising unique topical AD drug for children and adults with the potential for limitless long-term continuous use. Active, not recruiting --> Completed
- | zabalafin hydrogel (AB-101a) / Alphyn Biologics
New P2 trial: Study of topical AB-101 hydrogel versus vehicle in participants with atopic dermatitis. (EUDRACT) - Mar 7, 2022
P2, N=60, Not yet recruiting, Sponsor: Alphyn Biologics Australia Pty. Ltd., a subsidiary of Alphyn Biologics, LLC